AbbVie Inc. (NYSE:ABBV) Shares Sold by Moody Lynn & Lieberson LLC

Moody Lynn & Lieberson LLC trimmed its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 13.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,952 shares of the company's stock after selling 25,213 shares during the period. AbbVie makes up approximately 1.7% of Moody Lynn & Lieberson LLC's portfolio, making the stock its 17th biggest position. Moody Lynn & Lieberson LLC's holdings in AbbVie were worth $27,713,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. GGM Financials LLC increased its holdings in AbbVie by 0.7% in the 3rd quarter. GGM Financials LLC now owns 6,895 shares of the company's stock worth $1,362,000 after buying an additional 50 shares in the last quarter. Pine Haven Investment Counsel Inc boosted its holdings in shares of AbbVie by 0.3% during the 3rd quarter. Pine Haven Investment Counsel Inc now owns 18,102 shares of the company's stock valued at $3,575,000 after acquiring an additional 52 shares during the last quarter. Dillon & Associates Inc. boosted its holdings in shares of AbbVie by 0.8% during the 3rd quarter. Dillon & Associates Inc. now owns 6,914 shares of the company's stock valued at $1,362,000 after acquiring an additional 52 shares during the last quarter. First Citizens Financial Corp grew its stake in shares of AbbVie by 0.9% in the third quarter. First Citizens Financial Corp now owns 5,777 shares of the company's stock worth $1,141,000 after acquiring an additional 53 shares during the period. Finally, Sunflower Bank N.A. lifted its position in AbbVie by 0.4% during the third quarter. Sunflower Bank N.A. now owns 13,723 shares of the company's stock valued at $2,710,000 after purchasing an additional 53 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Trading Down 0.4 %

ABBV stock traded down $0.62 during midday trading on Friday, reaching $170.05. The company's stock had a trading volume of 5,584,343 shares, compared to its average volume of 4,522,214. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The firm has a market capitalization of $300.51 billion, a price-to-earnings ratio of 59.05, a PEG ratio of 1.68 and a beta of 0.58. The stock has a fifty day simple moving average of $175.84 and a two-hundred day simple moving average of $184.77. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, topping analysts' consensus estimates of $2.92 by $0.08. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.95 EPS. On average, equities research analysts predict that AbbVie Inc. will post 10.06 EPS for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $1.64 dividend. This is an increase from AbbVie's previous quarterly dividend of $1.55. The ex-dividend date is Wednesday, January 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.86%. AbbVie's payout ratio is 227.78%.

Insiders Place Their Bets

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the firm's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.25% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ABBV shares. Daiwa Capital Markets downgraded AbbVie from an "outperform" rating to a "neutral" rating and set a $180.00 price target for the company. in a research note on Thursday, December 5th. Piper Sandler Companies reaffirmed an "overweight" rating and set a $220.00 target price on shares of AbbVie in a report on Tuesday, December 17th. Citigroup dropped their price target on shares of AbbVie from $226.00 to $215.00 and set a "buy" rating on the stock in a research note on Tuesday, November 12th. JPMorgan Chase & Co. reduced their price objective on AbbVie from $210.00 to $200.00 and set an "overweight" rating for the company in a research note on Wednesday, November 13th. Finally, Argus upgraded AbbVie from a "hold" rating to a "buy" rating in a research report on Monday, November 4th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $205.50.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.